File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans

TitleSerum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans
Authors
Issue Date2008
PublisherAmerican Diabetes Association. The Journal's web site is located at http://diabetes.diabetesjournals.org/
Citation
Diabetes, 2008, v. 57 n. 5, p. 1246-1253 How to Cite?
AbstractOBJECTIVE-Fibroblast growth factor 21 (FGF21) is a metabolic regulator with multiple beneficial effects on glucose homeostasis and insulin sensitivity in animal models. This study aimed to investigate the relationship between its serum levels and various cardiometabolic parameters in humans. RESEARCH DESIGN AND METHODS-A newly developed immunoassay was used to measure serum FGF21 levels in 232 Chinese subjects recruited from our previous cross-sectional studies. The mRNA expression levels of FGF21 in the liver and adipose tissues were quantified by real-time PCR. RESULTS-Serum FGF21 levels in overweight/obese subjects were significantly higher than in lean individuals. Serum FGF21 correlated positively with adiposity, fasting insulin, and triglyc-erides but negatively with HDL cholesterol, after adjusting for age and BMI. Logistic regression analysis demonstrated an independent association between serum FGF21 and the metabolic syndrome. Furthermore, the increased risk of the metabolic syndrome associated with high serum FGF21 was over and above the effects of individual components of the metabolic syndrome. Our in vitro study detected a differentiation-dependent expression of FGF21 in 3T3-L1 adipocytes and human adipocytes. In db/db obese mice, FGF21 mRNA expression was markedly increased in both the liver and adipose tissue compared with that in their lean littermates. Furthermore, FGF21 expression in subcutaneous fat correlated well with its circulating concentrations in humans. CONCLUSIONS-FGF21 is a novel adipokine associated with obesity-related metabolic complications in humans. The paradoxical increase of serum FGF21 in obese individuals, which may be explained by a compensatory response or resistance to FGF21, warrants further investigation. © 2008 by the American Diabetes Association.
Persistent Identifierhttp://hdl.handle.net/10722/76693
ISSN
2014 Impact Factor: 8.095
2014 SCImago Journal Rankings: 3.922
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorZhang, Xen_HK
dc.contributor.authorYeung, DCYen_HK
dc.contributor.authorKarpisek, Men_HK
dc.contributor.authorStejskal, Den_HK
dc.contributor.authorZhou, ZGen_HK
dc.contributor.authorLiu, Fen_HK
dc.contributor.authorWong, RLCen_HK
dc.contributor.authorChow, WSen_HK
dc.contributor.authorTso, AWKen_HK
dc.contributor.authorLam, KSLen_HK
dc.contributor.authorXu, Aen_HK
dc.date.accessioned2010-09-06T07:23:56Z-
dc.date.available2010-09-06T07:23:56Z-
dc.date.issued2008en_HK
dc.identifier.citationDiabetes, 2008, v. 57 n. 5, p. 1246-1253en_HK
dc.identifier.issn0012-1797en_HK
dc.identifier.urihttp://hdl.handle.net/10722/76693-
dc.description.abstractOBJECTIVE-Fibroblast growth factor 21 (FGF21) is a metabolic regulator with multiple beneficial effects on glucose homeostasis and insulin sensitivity in animal models. This study aimed to investigate the relationship between its serum levels and various cardiometabolic parameters in humans. RESEARCH DESIGN AND METHODS-A newly developed immunoassay was used to measure serum FGF21 levels in 232 Chinese subjects recruited from our previous cross-sectional studies. The mRNA expression levels of FGF21 in the liver and adipose tissues were quantified by real-time PCR. RESULTS-Serum FGF21 levels in overweight/obese subjects were significantly higher than in lean individuals. Serum FGF21 correlated positively with adiposity, fasting insulin, and triglyc-erides but negatively with HDL cholesterol, after adjusting for age and BMI. Logistic regression analysis demonstrated an independent association between serum FGF21 and the metabolic syndrome. Furthermore, the increased risk of the metabolic syndrome associated with high serum FGF21 was over and above the effects of individual components of the metabolic syndrome. Our in vitro study detected a differentiation-dependent expression of FGF21 in 3T3-L1 adipocytes and human adipocytes. In db/db obese mice, FGF21 mRNA expression was markedly increased in both the liver and adipose tissue compared with that in their lean littermates. Furthermore, FGF21 expression in subcutaneous fat correlated well with its circulating concentrations in humans. CONCLUSIONS-FGF21 is a novel adipokine associated with obesity-related metabolic complications in humans. The paradoxical increase of serum FGF21 in obese individuals, which may be explained by a compensatory response or resistance to FGF21, warrants further investigation. © 2008 by the American Diabetes Association.en_HK
dc.languageengen_HK
dc.publisherAmerican Diabetes Association. The Journal's web site is located at http://diabetes.diabetesjournals.org/en_HK
dc.relation.ispartofDiabetesen_HK
dc.titleSerum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humansen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0012-1797&volume=&spage=57(5):1246&epage=53&date=2008&atitle=Serum+FGF21+levels+are+increased+in+obesity+and+are+independently+associated+with+the+metabolic+syndrome+in+humansen_HK
dc.identifier.emailTso, AWK: awk.tso@gmail.comen_HK
dc.identifier.emailLam, KSL: ksllam@hku.hken_HK
dc.identifier.emailXu, A: amxu@hkucc.hku.hken_HK
dc.identifier.authorityTso, AWK=rp00535en_HK
dc.identifier.authorityLam, KSL=rp00343en_HK
dc.identifier.authorityXu, A=rp00485en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.2337/db07-1476en_HK
dc.identifier.scopuseid_2-s2.0-48349146527en_HK
dc.identifier.hkuros140652en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-48349146527&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume57en_HK
dc.identifier.issue5en_HK
dc.identifier.spage1246en_HK
dc.identifier.epage1253en_HK
dc.identifier.eissn1939-327X-
dc.identifier.isiWOS:000255628700014-
dc.publisher.placeUnited Statesen_HK
dc.identifier.f10001100340-
dc.identifier.f10001100340-
dc.identifier.f10001100340-
dc.identifier.f10001100340-
dc.identifier.f10001100340-
dc.identifier.f10001100340-
dc.identifier.f10001100340-
dc.identifier.f10001100340-
dc.identifier.f10001100340-
dc.identifier.f10001100340-
dc.identifier.f10001100340-
dc.identifier.f10001100340-
dc.identifier.f10001100340-
dc.identifier.f10001100340-
dc.identifier.f10001100340-
dc.identifier.f10001100340-
dc.identifier.f10001100340-
dc.identifier.f10001100340-
dc.identifier.f10001100340-
dc.identifier.f10001100340-
dc.identifier.f10001100340-
dc.identifier.f10001100340-
dc.identifier.f10001100340-
dc.identifier.f10001100340-
dc.identifier.f10001100340-
dc.identifier.f10001100340-
dc.identifier.f10001100340-
dc.identifier.f10001100340-
dc.identifier.f10001100340-
dc.identifier.f10001100340-
dc.identifier.f10001100340-
dc.identifier.f10001100340-
dc.identifier.f10001100340-
dc.identifier.f10001100340-
dc.identifier.f10001100340-
dc.identifier.f10001100340-
dc.identifier.f10001100340-
dc.identifier.f10001100340-
dc.identifier.f10001100340-
dc.identifier.f10001100340-
dc.identifier.f10001100340-
dc.identifier.f10001100340-
dc.identifier.f10001100340-
dc.identifier.f10001100340-
dc.identifier.f10001100340-
dc.identifier.scopusauthoridZhang, X=9243825800en_HK
dc.identifier.scopusauthoridYeung, DCY=36869426200en_HK
dc.identifier.scopusauthoridKarpisek, M=23018519500en_HK
dc.identifier.scopusauthoridStejskal, D=7005865420en_HK
dc.identifier.scopusauthoridZhou, ZG=8417885800en_HK
dc.identifier.scopusauthoridLiu, F=55363556300en_HK
dc.identifier.scopusauthoridWong, RLC=26434054000en_HK
dc.identifier.scopusauthoridChow, WS=7402281153en_HK
dc.identifier.scopusauthoridTso, AWK=6701371436en_HK
dc.identifier.scopusauthoridLam, KSL=8082870600en_HK
dc.identifier.scopusauthoridXu, A=7202655409en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats